Nov. 26 at 8:59 PM
$VYGR Pathological cleavage or truncation of Tau often occurs at sites in the C-terminus (e.g., at Asp-421 or Glu-391), generating truncated fragments that are highly toxic and readily aggregate. JNJ's failed because they targeted P217, not the more toxic C-terminus as
$VYGR do.
In essence, the C-terminus is the region of Tau protein that mediates its main biological role—binding to microtubules—and is the part that undergoes the critical pathological modifications (hyperphosphorylation and aggregation) that define tauopathies.
$VYGR will be successful.
